Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 6/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23098217 | 0.89 | NOS2 (0.40) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL21085449 | 0.89 | NOS2 (0.38) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL21573981 | 0.89 | NOS2 (0.38) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL21573991 | 0.87 | RORC (0.40) | NOS2RORCIDH1 | |
| SCHEMBL24035554 | 0.87 | NOS2 (0.37) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL20925572 | 0.87 | MBOAT4 (0.39) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL21085388 | 0.86 | NOS2 (0.51) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL18973007 | 0.86 | CYP3A4 (0.40) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL20925737 | 0.85 | MBOAT4 (0.44) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 | |
| SCHEMBL20925551 | 0.85 | MBOAT4 (0.38) | NOS2CYP3A4CYP2C9CYP2C19KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022056439-A1 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | TRITERPENOID THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021231208-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| EP-3353190-B1 | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES | REATA PHARMACEUTICALS INC (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-2558105-B1 | BARDOXOLONE METHYL FOR THE TREATMENT OF OBESITY | REATA PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3492077-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | Reata Pharmaceuticals, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2252283-B9 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |